Activity Report 2017

16 Apr 2018

During its first full year in operation, GARDP developed a business plan that articulates a seven-year roadmap, prioritizing sepsis in newborns and STIs – two disease areas of high global public health need on which to focus our R&D efforts.

Our plans for 2018 are even more ambitious. These include: starting a global observational study, and two clinical trials; developing new public and private partnerships; accelerating our work to recover molecules for their potential value for antimicrobial drug development; and recovering and sharing the knowledge of established antimicrobial researchers with those starting their careers.

View in:


We use cookies to provide you a better experience and understand how our site is being used. To consent to the use of cookies, click ‘Accept’. Learn more about our cookie and privacy policy.